Abstract
Objective: To compare the clinical effect and safety between letrozole (LE) and clomiphene citrate (CC) stimulated cycles in women with polycystic ovary syndrome (PCOS). To evaluate the effectivenesses and benefits of letrozole for ovulation induction in infertile women with PCOS. Methods: We retrospectively analyze the clinical data of 242 cases of the first ovulation induction cycle patients with PCOS, who referred to the Department of Reproductive Medicine, The First Affiliated Hospital of Yangtze University from June 2016 to June 2018, and were randomly divided into letrozole group and control group. The experimental group received Letrozole 2.5 mg/d for 5 days during days 3 - 7 of menstrual cycle. The control group was given clomiphene citrate 100 mg/d for 5 days during days 3 - 7 of menstrual cycle. Progynova will be used when the follicular diameter is 14 mm. Results: Letrozole group had less mature follicles, lower estrogen levels, thicker endometrium and higher ovulation rate in HCG day. But there is no difference between two groups in clinical pregnancy rate, single pregnancy rate, abortion rate, prenatal pregnancy delivery and newborns. Conclusion: Letrozole and clomiphene citrate have similar effect on ovulation induction, but we still need a lot of clinical data of letrozole about the safety of follicle, embryo, fetus and newborns.
Highlights
Polycystic ovary syndrome (PCOS) is caused by a variety of factors
We retrospectively analyze the clinical data of 242 cases of the first ovulation induction cycle patients with polycystic ovary syndrome (PCOS), who referred to the Department of Reproductive Medicine, The First Affiliated Hospital of Yangtze University from June 2016 to June 2018, and were randomly divided into letrozole group and control group
Clomiphene citrate (CC) is the first-line ovulation-promoting drug recommended by the World Health Organization (WHO)
Summary
Polycystic ovary syndrome (PCOS) is caused by a variety of factors. J. Yi or rare ovulation is one of the main reasons for infertility. The etiology of PCOS has not been completely clarified, there have been many years of historical experience in the induction of ovulation therapy for PCOS. Clomiphene citrate (CC) is the first-line ovulation-promoting drug recommended by the World Health Organization (WHO). During the clinical observation process, CC resistance was found in many patients, affecting cervical mucus, and affecting the side effects of submucosal intima, thereby affecting pregnancy outcomes. Letrozole (LE) is a third-generation selective non-steroidal aromatase inhibitor that induces ovulation by inhibiting estrogen production. The ovulation effect and safety of LE are in the end
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
